Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
Aktis Oncology, Inc.
Mayo Clinic
University of Washington
Northwestern University
Centre Hospitalier Universitaire, Amiens
University of Washington
University Medical Center Groningen
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University College, London
National Cancer Institute (NCI)